Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available publicly. This is exciting, but also offers serious and critical challenges in valuation. The focus of this seminar briefing is on those challenges.
This OHE publication by Nick Timmins, a senior fellow at the Institute for Government and the Kings Fund, sets out arguments in favour and against. It is based on the seminar he gave at OHE in July 2018.
This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2) why the UK biotech firms that do exist have not brought blockbuster drugs to the market and (3) what the implications are for industrial strategy after Brexit. These remarks are based primarily on research we completed for our recent book, Science, the State and the City (Owen and Hopkins, 2016), with some additions and specific observations about the potential effects of Brexit.
This seminar focuses on the NHS staffing markets and the use of temporary staff, specifically in the NHS provider sector, i.e. foundation trusts and NHS trust. (which include hospitals). To provide background and context, the discussion begins with an overview of the NHS labour market and the role of staffing agencies in providing temporary staff. The core of the seminar is an examination of previous strong growth in expenditure on such staffing, particularly during the early part of this decade; the effects to date of government intervention to address that spending; and possible lessons for other sectors from the limited evidence now available.
This OHE Seminar Briefing summarises a seminar given by Professor David Grabowski, which provided a health economics perspective on how payment and delivery interventions can encourage high-value nursing home care. It took lessons from the U.S. effort to encourage high-value care and applied them to the UK, where we have similarly relied on regulation as the key guarantor of quality.
This OHE Seminar Briefing summarises a seminar given by Dr Nicholas Hicks, Co-founder and Chief Executive of COBIC (Capitated Outcomes-Based Incentivised Care). Dr Hicks describes COBIC’s outcomes-centred approach that has been adopted by NHS services across England and that brings together commissioners, providers, other professions, patients and carers.
This OHE Seminar Briefing summarises a seminar given by Professor Luigi Siciliani on waiting time policies in the health sector from an international perspective, and highlights which policies have worked well in the last decade in OECD countries. Professor Siciliani also touches on methods for comparing waiting times internationally and where the UK stands in the international figures. Finally, the Briefing discusses waiting time inequality by socioeconomic status.
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.
It is often argued that the demands for increased healthcare expenditure arising from an ageing population, advancing technologies, and increasing expectations, warrant higher healthcare budgets. Professor Stephen Birch argues that this reactive approach is not sustainable, and that the perceived mismatch between resources and demand is due to poor health service planning. In this briefing, based on an OHE lunchtime seminar, Professor Birch presents a framework to re-focus planning models on population needs.